What's Happening?
Arrowhead Pharmaceuticals has received marketing authorization from the European Commission for its drug REDEMPLO (plozasiran), designed to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). This approval is significant
as REDEMPLO is the first small interfering RNA (siRNA) medicine authorized for FCS without requiring genetic confirmation of the condition. The decision was supported by data from the Phase 3 PALISADE study, which demonstrated an 80% reduction in triglycerides and an 83% reduction in acute pancreatitis incidence among patients treated with REDEMPLO compared to placebo. The drug works by targeting and suppressing the production of apolipoprotein C-III, a protein that raises triglyceride levels.
Why It's Important?
The approval of REDEMPLO marks a pivotal advancement for patients with FCS, a rare and severe condition characterized by extremely high triglyceride levels and a heightened risk of acute pancreatitis. This condition significantly impacts patients' quality of life, and current treatment options are limited. By not requiring genetic confirmation, REDEMPLO can potentially be administered to a broader patient population, addressing an unmet medical need. The drug's approval also underscores the potential of Arrowhead Pharmaceuticals' TRiM platform in developing RNAi-based therapies for diseases with significant unmet needs, potentially paving the way for further innovations in genetic medicine.
What's Next?
Following the European Commission's approval, Arrowhead Pharmaceuticals plans to engage with national health authorities across the EU to facilitate the drug's availability to patients. The company is also conducting additional Phase 3 studies to explore REDEMPLO's efficacy in treating severe hypertriglyceridemia. These efforts could lead to expanded indications and further regulatory approvals, enhancing the drug's market reach. The ongoing success of REDEMPLO may also bolster Arrowhead's position in the pharmaceutical industry, encouraging further investment in RNAi therapeutics.
